We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Evgen are working on a treatment not a test. Don't compare apples with umm, peas. They are about to start phase 2 trials for ASD this year. OBD have done their own clinical trials and will be maintaining records of the tests they're selling through their clinic I expect. They haven't done any large scale credible trials or been approved by regulatory authorities have they? So this is why they aren't selling at scale.
Evgen have been granted orphan status by the FDA for one product in their pipeline. Phase 2 trials for ASD are a big deal. Working with Staclica who are working with Novartis is a big deal. In Aim, PIs are 'the market' for a long time. We aren't on the radar. If/when this next stage is announced we will get on the radar with PIs and IIs.
DS - Well I've made my opinion and views pretty clear I suppose, so going forward I'll observe from the sidelines. My final comment is BUYERS BEWARE. I will be back when these break 1p, I wouldn't want you to miss me.
Ralf, have you considered that Stalicla have taken a different approach...
Six years, close to $100M invested and you would have everyone believe they are passing in the wind...
https://stalicla.com/
Stalicla's partner Firefly Neuroscience edging forward with NASDAQ listed Wave Dancer (forms filed this week)...
https://stalicla.com/news/press/firefly-neuroscience
If Evgen isn't for you (you had a little punt not so long ago) why persist in the negative posts ?
It's not like many people post on here lol
Pro - maybe you could help me answer this question, they have a product in the market already, the size of the potential market is enormous, so in my eyes I could have well underestimated it.
Evgen have a product that is still at a clinical stage, hasn't been proved to work on anything yet, the trails that it was aimed at failed miserably and a set of bods who wouldn't touch the shares with a barge pole. The shares are in a constant decline, a major shareholder has just pulled out and an imminent cash call that will destroy existing shareholders value is only months away.
Stalicla is one of many that has delved into this, all the other trials failed but you suddenly expect this to miraculously deliver and change the companys fortune around over night.
Smell the coffee mate, you're just one of many who have been trying to ramp this up over the years and all ends up in the same place.
Oh and you still haven't answered my question. Do you think OBD is worth £5.7B or £41 a share? Both would make it a FTSE 100 company.
I find it astonishing that you can make such outlandish claims and then have the gall to suggest that we're the ones not thinking straight. Absolute mindbogglingly.
Oh the irony and contradictory nature of that comment does make me chuckle.
The fact is Alf, I have never said OBD is worthless, like you do here. I have simply objected to your idiotic valuation, and stated the fact that they will be under 15p last week (they went this so I was correct here). I also stated that I don't believe they will raise above 15p, again I am on track to be correct. I even think they may struggle to get a raise away at 10p now. So no, I won't look silly if OBD actually starts to sell their tests and see their valuation increase. Although this certainly won't happen any time soon.
However, Evgen have already received $500k from Stalicla and have invoiced another $500k. So you are incorrect about them not receiving, or having any hope on receiving a penny.
It will be yourself lookimg silly when Evgen confirm they have received the next $500k from Stalicla. You will then look even more silly when they confirm IND has been applied for, and subsequently granted leading to the $5m payment.
You will also look silly when OBD continues to fail to meet your ludicrous target. The funny thing is you've been sprouting nonsense about a discounted cash raise here but for some reason believe that OBD have something up their sleeve when the cash runs out in two months.
Pro, I may have been wrong a couple of times regarding Evgen expecting a short term bounce that never fully materialised but overall I've been right. My current prediction is that these will be
trading sub 1p and they'll never see a penny from Stalicla. The potential for OBD speaks for itself, you'll look somewhat silly if only a fraction of their potential is realised.
Kingalf,
How can you possibly talk about disillusioned investors when you think OBD is worth £5.7B or £41 a share? I'm not sure which is your true prediction because the numbers don't add up. - £41 a share would be over £8.2B, as there are 202m shares in issue.
However, OBD has to gain over 25000% to reach your target. The audacity for you to call investors here disillusioned is astonishing. I don't think anyone here has made such a moronic statement for Evgen.
I'm sorry you bought in too early CJ. I am not angry with anyone. You are a troll though. Maybe just don't be one anymore. New Year's resolution?
Tricky
You, Pro and all these other existing crop of disillusioned investors will find out to your expenses that it's the bods you should be aiming your criticism and anger at rather than myself, CJ and Radar.
I love that. Call someone a troll because they are critical and sceptical of the company. Your comments may have some credibility except for the fact you’re missing one key point. You do realise this is the lowest the share price has ever been? In April 2019 the share price was 23.4p. It is now about 1.6p. If you bought £10k worth of shares at that date less then 5 years ago your shares would be worth £684. So it’s being a troll to be critical of a company who’s share price has fallen so far? Are you serious? Do you think people buy shares for the fun of it or to try and invest and make money? You clearly aren’t bothered about shareholder value.
If anyone is a troll it’s you. People like you are responsible for people coming on to these messageboards and investing in dud shares. If you listened to people like kingalf you would have saved a lot of money.
In case anyone missed this last week. GLA
You and CJ are just a couple of trolls or bitter and disappointed investors who can't cope with the way markets work. AXA are buying commercial property now. They are leasing it back to previous owners and no doubt making good returns from that right away. I can't afford to buy commercial property but I can afford to invest judiciously on stocks.
EVG has g8 potential. Stalica have just raised $17 million for phase 2 trials on both autism spectrum candidates, STP1 and EVG's STP2 and for trials on Novartis' candidate for treating alcohol and cocaine addiction. Credible, £billion + pharma agreement in place. The market will follow the news once an announcement is made as it always does. Very few examples where the market gets ahead of news really.
my prediction is that these will be trading at a fraction of 1 pence within the year.
way too much emphasis on the stalicla payment going through which not only myself and cj39 think is fanciful, but also the market, as well as the bods as they would have been fully invested had they thought differently.
every 6 months or so you get a new wave of investors talking this up, ****ging off any dissenting opinions only to be shown to be wrong by the market. the current crop are no different.
**** We’ve only agreed for Stalicla to the sole rights of SFX-01 for ASD. Agreement signed & Potential for that alone £161M.
However, We’re in our stall to the whole market for SFX-01 for a number of other indications.
Current MCap £4.5M.
Good luck de-ramping that.
CJ, you are not in a position to ascertain whether EVG will receive the funds from Stalicla, or not.
Evgen have an agreement with Stalicla, so they can’t simply ‘buy it out for £10M’, have you not been in business before?
Furthermore, the cash flow of Evgen is of no interest to Stalicla, Evgen is listed and has a number of options for any funding it requires.
Lastly, one should consider the fact that Evgen attracted the interest from a Company such as Stalicla, it signed a phenomenally large agreement with them, don’t imagine that other large Pharmaceutical Companies won’t also come to our table.
Mozax, EVG will never ever get that money. There is something people are totally overlooking here. If SFX-01 is effective why would Stalicla potentially pay EVG $161m in payments plus royalties when the could buy the company out for about £10m right now?
Stalicla know that EVG are short on cash with no other income streams. What is to say that the delay in these payments isn’t part of a plan to pick EVG up for peanuts later in the year?
It’s amazing to think that there is a potential £161M deal, already signed & agreed, but the market has not given it even a 1% chance of concluding at this moment in time.
I’ve said this before, but the £5M milestone payment will be seen as paving the way for full implementation of the agreement, and subsequent massive rerating.
In fairness to the trolls and general retail investors, I believe it was AXA that sold down a large holding here all the way into the 1.3p area, and seeing an investment continually disappearing is hard to bear.
I’m currently building a big position as I think this has been heavily oversold, but also, I believe in what Evgen are working on, and it’s an enormous market.
No-one said trials will take place in 2 weeks CJ. The next RNS, should follow soon and will probably be the outcome of the phase 1 analysis- which we know from a previous RNS was good. It will have implications for the design of the trials. Stalicla will be using their platform to determine which patients should receive STP1 and which should receive STP2 depending on their DNA and other genetic data. So a complex process. This is very exciting for anyone interested in autism spectrum disorder. We should hear all about it in the next RNS and corresponding promotional work. The market is massive. 1/36 adults in the US have ASD and 1/100 children have it here in the UK. Once we get confirmation of next steps this will move on that news because that news has ground breaking implications for personalised medicine and for ASD.
After that, news flow should be about application to the FDA for approval for trials, recruitment for trials, trial commencement, early results, end results, milestone payments, additional licensing, investment, possibly a takeover if everything goes well.
Amazing things don't happen overnight. The sp is down here because you and other trolls have taken advantage of the time lag in news. Once we get confirmation of the news on the Stalicla site and next steps this sp should be history. Unless you are right and the scientists at Stalicla and EVG don't know what they're doing and are a bunch of con artists. I'm going with the amazing CEO at Stalicla, a woman who has a fantastic reputation in the scientific community and the EVG team, on that bet.
GLA.
Exactly DSFlat. This would have been a great time for Stalicla to dump SFX-01 if they had any intention to. However, they have instead updated their guidance and reaffirmed that they are planning for STP2 to enter phase 2 trials this year.
We know that before Phase 2 trails can commence, IND is needed from the FDA so this MUST be applied for, and not objected to, before trials can commence. Within 30 calendar days of application we will know if IND has been accepted as after 30 days approval is automatic - the FDA have 30 days to object, although all available safety data for SFX-01 would suggest no objections should occur.
We also know that Stalicla will be due to pay Evgen $5m on approval of IND. Therefore, it is reasonable to presume that Evgen will receive the monies due before cash runs out towards the end of the year, avoiding the need for any placement.
"STP2 will enter Phase 2 in 2024"
Is what Stalicla Website states...
https://stalicla.com/pipeline
Someone knows something.
There are a lot of people who think the Stalicla money is coming any time now, some even suggested this week. I would be very surprised, the last update by EVG two weeks ago stated:
The companies are engaged in analysis and interpretation of Evgen's recent Phase 1b healthy volunteer PK/PD study and the implications for a future Phase 2 trial in ASD
Anyone who thinks that will be done in a couple of weeks has rocks in their head and should go and see a psychiatrist, they are mental.
I've also only just spotted that your £5.7 billion pound valuation and £41 a share doesn't add up. Clearly mathematics is not your strong suit, and neither is science, or investing for that matter.
You claimed £5.7 billion valuation is equivalent to £41 a share, but with just over 200 million shares in issue for OBD this doesn't make sense. Oh dear oh dear.
Taking a number and dividing is simple, but still you managed to mess it up Kingalf.
I have no clue who money munch is, however, they clearly got under your skin. If you search, you will see that the account you are referring to is still very much active with the last post on the 22nd of Jan 2024, albeit they are invested in a different share from the looks of it. You would also note the writing style between this other account and myself is vastly different. They seem to copy and paste a lot which I do not do, while the language we use is also vastly different (You can find them by going back through the Evg pages).
Nice attempt to try to discredit me though. And it seems like you have done the same amount of research and due diligence suggesting this account, and myself, are related to one another as you do with your investments. I.e. none.
Again, more lies from you on the cash raise front, but what should we expect? Your history is clear for all to see. You spend all your time on a share BB you aren't invested in, spreading lies and misinformation in an attempt to make yourself feel better about your loss here. It must have hit you hard, otherwise why would you stay here?
Going to be even worse for you when confirmation comes through that Stalicla have applied for IND from the FDA for STP2. Then even worse when IND is approved and Stalicla have to pay Evgen $5m. Or are you suggesting that is deal with Stalicla is fake and simply a rouse by the bod, by which they would be committing fraud and liable to severe prosecution? You still haven't explained why Stalicla won't pay Evgen when they are contractually obligated to do so if the milestones are reached.
OBD hardly have a proven product, no one is buying it and I don’t think they will until they have proven during large scale, randomised trials that it is more effective than the PSA test currently available. The sale figures to date prove this. OBD will continue to drop until finding is sorted and you’ll be even further in the hole. Again, you seem to have bought the hype without doing much due diligence. OBD is going to be yet another painful lesson for you. The question is, are you going to hang around there to deramp that share as well?
While a heavily invested bod can be a good thing, it means very little when investor confidence has been shattered and cash is needed. Many companies with a heavily invested bod end up in administration and simply having a bod invested doesn't mean they have PI interests at heart. OBD bod are at the mercy of investors and what IIs are prepared to pay for the impending cash raise. From the last update, I don’t expect it to be pretty for OBD.
And do you still stick by your pie in the sky valuation of £5.7 billion, £41 a share, while the Market Cap is barely over £30 million, 16p?
Is that you money munch ?
Pro you seemed to join in September 2022 at about the same time MM disappeared.
It's important because MM was a serial ramper and was singled out by many on here for being so. Similar to yourself Pro, he/she would post endlessly to bury any negative posts and round on anyone with a contrary view. Give it a few more months and Evgen will announce another placement that will decimat existing shareholder value. Admittedly shareholders can vote against, but the alternative will be oblivion.
OBD also need to raise cash, but the bods are heavily invested and will want to minimise shareholder pain. They have a proven product in the market, while Evgen are still at the basement level hoping Stalicla will pay out when it would be more cost effective to delay any payment until next year and then pick up the rights from the receivers for peanuts.
We'll see who ends up with egg on their face, but by then you'll be using a different alias and ramping another dead beat share